JERSEY CITY, N.J. -- Organon (NYSE: OGN), a global healthcare company  with a focus on women’s health, announced it has expanded its agreement  with Eli Lilly and Company (Lilly) to become the sole distributor and  promoter for the migraine medicine Emgality (galcanezumab) in the  following additional markets: Canada, Colombia, Israel, South Korea,  Kuwait, Mexico, Qatar, Saudi Arabia, Taiwan, Turkey and the United Arab  Emirates. This expanded partnership builds on Organon’s role as sole  distributor and promoter of Emgality in Europe since February 2024.

 Emgality, a humanized monoclonal antibody calcitonin gene-related  peptide (CGRP) antagonist, is indicated for the preventive treatment of  migraine in adults, and in some markets, the indication specifies  prophylaxis for those with at least four migraine days per month.  Emgality is also indicated in some markets for the treatment of episodic  cluster headache in adults.

 “The broadening of this agreement is a testament to Organon’s  best-in-class commercialization capabilities, global footprint and deep  expertise in women’s health,” said Kevin Ali, Organon CEO. “We know that  migraine ranks as the leading cause of disability among young women  and we’re proud to expand our offering to more women and men around the  world living with episodic or chronic migraine.”

 Migraine is one of the most prevalent neurological disorders  worldwide causing recurrent moderate-to-severe headaches, often  accompanied by other debilitating symptoms, including nausea, vomiting,  and sensitivity to light and sound. Untreated migraine attacks can  last from four to 72 hours. Many of these symptoms can still be  experienced between migraine attacks, although less frequently and with  less intensity, contributing to a reduced quality of life and causing  worry for patients in anticipation of the next attack.

 “We are thrilled to expand this collaboration agreement with Organon,”  said Ilya Yuffa, executive vice president of Eli Lilly and Company and  president of Lilly International. “We’re confident in our shared mission  to bring this important migraine treatment to more patients around the  world.”

 Under the terms of the agreement, Organon will become the sole  distributor and promoter of Emgality in the following additional  markets: Canada, Colombia, Israel, South Korea, Kuwait, Mexico, Qatar,  Saudi Arabia, Taiwan, Turkey and the United Arab Emirates. Lilly will  remain the marketing authorization holder and will manufacture the  product for sale.

 Total consideration to be paid to Lilly for the expansion of  territory includes an upfront payment of $22.5 million as well as  sales-based milestone payments.